Nutriband Inc. (NASDAQ: NTRB), a company focused on developing transdermal pharmaceutical products, announced that its CEO and Co-Founder Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit. The presentation will be part of the CEO Spotlight event scheduled for Aug. 26, during the two-day summit held Aug. 25-26 at the Sandy Springs Performing Arts Centre in Sandy Springs, Georgia.
The summit gathers leaders from biotechnology, medical technology, research, manufacturing, and investment sectors. Nutriband's participation underscores its commitment to addressing critical issues in pharmaceutical safety, particularly the abuse and diversion of drugs with abuse potential.
Nutriband is currently developing AVERSA™, an abuse-deterrent transdermal technology designed to incorporate aversive agents into patches. This technology aims to prevent abuse, diversion, misuse, and accidental exposure of drugs that have the potential for abuse. The company's lead product is an abuse-deterrent fentanyl patch that utilizes AVERSA™, which could significantly impact the opioid crisis by making it harder to misuse prescription fentanyl.
The CEO Spotlight at the summit provides a platform for Nutriband to highlight its innovative approach to a pressing public health issue. By presenting to industry leaders and investors, Nutriband seeks to attract attention to its technology and potentially forge partnerships that could accelerate development and commercialization.
The implications of AVERSA™ are substantial. If successful, the technology could set a new standard for transdermal drug delivery systems, particularly for opioids and other controlled substances. This could lead to safer pain management options, reduced rates of addiction and overdose, and lower healthcare costs associated with substance abuse.
Nutriband's participation in the summit also reflects the growing importance of abuse-deterrent formulations in the pharmaceutical industry. Regulatory agencies have encouraged the development of such technologies, and the market for them is expanding. Nutriband's presentation may influence investor sentiment and contribute to the broader dialogue on how to mitigate drug abuse.
For more information about Nutriband and its pipeline, visit the company's newsroom at https://ibn.fm/NTRB. The full press release can be accessed at https://ibn.fm/Un3ax.
